Introduction:
Invasive Aspergillus infection (IA) is a major cause of morbidity and mortality in lung transplantation (LT) patients (1) . IA ]. Though prophylaxis is crucial, the optimal strategy for preventing IA is uncertain (3) . Itraconazole (ITCZ) has been reported to exhibit significant activity against Aspergillus spp. and other fungi (4) . At Kyoto University Hospital in Japan, we administered ITCZ prophylaxis to all patients undergoing LT. According to a previous study, IA developed a median of 96 days after transplantation, with 51% occurring within 90 days and 72% occurring within 180 days after transplantation (6) . In our hospital, we think that antifungal prevention is partly effective, and as a consequence, the onset rate is comparatively low and the onset time is late. Among 30 patients in this study, 9 patients were administrated ITCZ for more than 1 year. None of them (9 patients) were diagnosed with IA. Twenty one patients stopped ITCZ administration within 1 year and 5 (24%) patients developed IA.
We suppose at least 1 year prophylaxis is necessary. Because of a small sample size and short observation period, further investigation is needed to decide adequate duration of prophylaxis.
Next, we examined the risk factors of IA in LT patients using univariate analysis ( Table   2 ). Factors associated with IA development were CMV infection, renal replacement therapy and tracheotomy. Because of the small sample size, there was no significant difference, but advanced age and acute rejection tended to be associated with IA development (Table2), which was compatible with a previous report (7) . SLT did not suppose a significant risk for IA in our study. It is probably because none of our patients had airway colonization with Aspergillus before transplantation (data not shown) and were not diagnosed with cystic fibrosis, which is a predictive factor of Aspergillus colonization (8) .
It is convincible that Aspergillus was acquired after stopping ITCZ because all the 5 IA as a result to ineffective early prophylaxis. Either, both or more mechanism are responsible for IA, but that is not confirmed. Further studies are required to investigate potential mechanisms of IA after LT.
Optimal prophylaxis strategies for lung transplant recipients remain poorly defined. 2008;32(2):S161-S165]. We began to administer nebulised amphotericin B with ITCZ.
We will evaluate combination therapy of nebulized amphotericin B and ITCZ including therapy duration.
In conclusion, IA remains a devastating disease in lung transplant patients. We need to reconsider the duration of ITCZ prophylaxis, we think that a prophylactic administration for at least 1 year after transplantation would be reasonable especially to patients considered to be at high risk of IA. CMV infection, renal replacement therapy and tracheotomy were risk factors for IA. 
